Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
The evolution of hematopoietic cells under cancer therapy.
Pich O, Cortes-Bullich A, Muiños F, Pratcorona M, Gonzalez-Perez A, Lopez-Bigas N. Pich O, et al. Among authors: cortes bullich a. Nat Commun. 2021 Aug 10;12(1):4803. doi: 10.1038/s41467-021-24858-3. Nat Commun. 2021. PMID: 34376657 Free PMC article.
Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome.
Guijarro F, López-Guerra M, Morata J, Bataller A, Paz S, Cornet-Masana JM, Banús-Mulet A, Cuesta-Casanovas L, Carbó JM, Castaño-Díez S, Jiménez-Vicente C, Cortés-Bullich A, Triguero A, Martínez-Roca A, Esteban D, Gómez-Hernando M, Álamo Moreno JR, López-Oreja I, Garrote M, Risueño RM, Tonda R, Gut I, Colomer D, Díaz-Beya M, Esteve J. Guijarro F, et al. Among authors: cortes bullich a. Blood Adv. 2023 Oct 10;7(19):5799-5811. doi: 10.1182/bloodadvances.2023009742. Blood Adv. 2023. PMID: 37450374 Free PMC article.
Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.
Jiménez-Vicente C, Martínez-Roca A, Pomares H, Castaño-Diez S, Guijarro F, López-Guerra M, Bataller A, Esteban D, Cortés-Bullich A, Pérez-Valencia AI, Guardia-Torrelles A, Zugasti I, Rovira M, Fernández-Avilés F, Colomer D, Arnan M, Díaz-Beyá M, Esteve J. Jiménez-Vicente C, et al. Among authors: cortes bullich a. Leuk Res. 2023 Dec;135:107403. doi: 10.1016/j.leukres.2023.107403. Epub 2023 Sep 30. Leuk Res. 2023. PMID: 37837718 No abstract available.
Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
Cortes-Bullich A, Perez A, Bachmeier C, Mhaskar R, Chavez JC, Shah B, Nishihori T, Khimani F, Lazaryan A, Davila ML, Locke FL, Jain MD. Cortes-Bullich A, et al. Transplant Cell Ther. 2021 Sep;27(9):768.e1-768.e6. doi: 10.1016/j.jtct.2021.05.018. Epub 2021 May 30. Transplant Cell Ther. 2021. PMID: 34077811 Free PMC article.
Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
Castaño-Díez S, Pomares H, Esteban D, Guijarro F, Jiménez-Vicente C, Zugasti I, Álamo JR, Mayayo VT, López-Guerra M, de la Fuente C, Charry P, Cortés-Bullich A, Bataller Á, Maluquer C, Colomer D, Rozman M, Arnan M, Xicoy B, Esteve J, Díaz-Beyá M. Castaño-Díez S, et al. Among authors: cortes bullich a. Br J Haematol. 2023 Nov 27. doi: 10.1111/bjh.19217. Online ahead of print. Br J Haematol. 2023. PMID: 38013238